Member Info for Energyshares

Hurst are you sure it was Broad Street and not Sesame Street.

https://m.youtube.com/watch?v=j4Zd-jIFioA

I’m back in the black at £1.32 let’s hope all LTH’s find their break even and push on into profit very soon.
GLA

https://m.youtube.com/watch?v=mmn_g8R1r3s

Up to 16 shots just on precision then double that on TMac
Don’t forget :
Point
LG Chem
Daewoong
Affyxell
Moderna ? ( never updated)
Astrea Bioseparations

Then mysterious Diagnostic division

Yep your right their Timster…..

If you read again,I said just as they received Home Use with EU and ROW markets awaiting. Not commercial.
What a to55er

He told us he sold shares to buy a home for his family.

He didn’t have to say that.

He stopped sale of LFT just as it received home use because it was not up to his standard.

Missing out on Millions of sales.

He has kept the trial going with cancer patients living in hope.

I trust his integrity this is working….

BEGO ESMO

I think it will move quick once ELMO turns up.

Well the shorters had plenty of time to exit,
If they are caught with their pants down they only have themselves to blame.

Burn Burn shorts…….

Here is AS again 2mins 58 secs ,3 years ago still talking about large Pharma and TMac early days.
https://m.youtube.com/watch?v=1QPyhGsJNFc

AS and Bill Bachovchin talking to Large Pharma 4 years ago before they started partnership.

Very Interesting…
Have they been holding hands with Large Pharma from the start.

https://m.youtube.com/watch?v=XxMY3Hmhgnw

AS & Neil Bell just as they release the Data RNS

https://m.youtube.com/watch?v=8g_GeQR8fJo

Looks like Bill files one a month.
Look at this list of patents:
https://uspto.report/company/Bachovchin-William-W

Good spot Gadgie

Daewoong Pharmaceutical and Avacta plan to invest the secured funds in the development of new drugs. The field that both companies are focusing their capabilities on is next-generation cell gene therapy. Based on Daewoong Pharmaceutical's mesenchymal stem cell platform 'DW-MSC' technology, we developed 'AffyXell', a fusion of Avacta's affimer platform technology, a type of non-immunoglobulin scaffold protein, to strengthen immune regulation function. do. In the field of cell and gene therapy, it plans to create a therapeutic that overcomes the limitations of existing antibodies and stem cells.

By combining the two technologies, it is possible to develop therapeutic agents for immune and autoimmune diseases. It is thanks to the immunomodulatory function of DW-MSC and the target activity regulation function of Apimer. DW-MSC overcomes the short lifespan and productivity limitations of the existing adult tissue-derived mesenchymal stem cells, and Apimer has the same role as an antibody, but has an advantage in tissue delivery due to its low price and small size.

The pipeline attracting industry attention is AFX001. Daewoong Pharmaceutical and Avacta are developing AFTX001 for organ transplant rejection and graft-versus-host disease. It plans to complete preclinical trials by next year and start an IND application for phase 1 clinical trials in the second half of that year. We confirmed the final excellent drug apimer that can exhibit antagonistic action against mouse and human target proteins, and introduced it into DW-MSC to construct the apicell cell line.

Meanwhile, Daewoong Pharmaceutical and Avacta succeeded in attracting 8 billion won in Series A investment last year. Apicell Therapeutics is a joint venture established in February 2020 by Daewoong Pharmaceutical and Avacta Corporation by granting technology licenses to both companies for the purpose of researching function-enhanced stem cells and developing therapeutics based on them.

Apicell Therapeutics strengthened its capabilities by collaborating with Samsung Seoul Hospital in May to exchange trends and technical information in the field of gene-transduced mesenchymal stem cell therapy, and to research national projects related to cell and gene therapy development.

2023 looks very good for Avacta

Wiggly extra patent filed 8 weeks after DE1 and 2 weeks after Avacta announced poster presentation via Twitter.

What did they see with DE1 to add to the patent……

Roll on Sep
GLA

Great find gmcc.
This looks very promising if Bill Bachovchin is adding to his patents in the middle of a trial they must be seeing some good results.

SP starting to move to 2nd base
;)

Doing my bit for womens sport Timster
;)

Natalie Cook head of Manchester Trials tweeted the other day.

Fabulous fun in the ?? on Wed at the @TheChristieNHS Annual rounders tournament with our team “Phase 1 Hit Wonders”. Lots of research teams entered, perhaps a research rounders league for next year!

Love their name team “Phase 1 Hit Wonders”.
Now I wonder……….Could it be us

https://m.youtube.com/watch?v=kRiUEr89ep0